Find Viloxazine Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 35604-67-2, 2-((2-ethoxyphenoxy)methyl)morpholine hydrochloride, Viloxazine hcl, Vivalan, Emovit, Vicilan
Molecular Formula
C13H20ClNO3
Molecular Weight
273.75  g/mol
InChI Key
HJOCKFVCMLCPTP-UHFFFAOYSA-N
FDA UNII
OQW30I1332

Viloxazine Hydrochloride
A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.
1 2D Structure

Viloxazine Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride
2.1.2 InChI
InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H
2.1.3 InChI Key
HJOCKFVCMLCPTP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCOC1=CC=CC=C1OCC2CNCCO2.Cl
2.2 Other Identifiers
2.2.1 UNII
OQW30I1332
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Emovit

2. Ici-58,834

3. Ici58,834

4. Viloxazine

5. Viloxazine Hydrochloride, (r)-isomer

6. Viloxazine Hydrochloride, (s)-isomer

7. Viloxazine Oxalate (1:1)

8. Viloxazine, (+-)-isomer

9. Viloxazine, (r)-isomer

10. Viloxazine, (s)-isomer

11. Vivalan

2.3.2 Depositor-Supplied Synonyms

1. 35604-67-2

2. 2-((2-ethoxyphenoxy)methyl)morpholine Hydrochloride

3. Viloxazine Hcl

4. Vivalan

5. Emovit

6. Vicilan

7. 2-[(2-ethoxyphenoxy)methyl]morpholine Hydrochloride

8. Rac Viloxazine Hydrochloride

9. Viloxacina Clorhidrato

10. Ici 58,834

11. Viloxazine Hydrochloride [usan]

12. 2-((2-ethoxyphenoxy)methyl)morpholinehydrochloride

13. 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride

14. 2-((o-ethoxyphenoxy)methyl)morpholine Hydrochloride

15. Spn-812

16. Oqw30i1332

17. Qelbree

18. 2-[(2-ethoxy Phenoxy)methyl]morpholine Hydrochloride

19. Morpholine, 2-((2-ethoxyphenoxy)methyl)-, Hydrochloride

20. Morpholine, 2-[(2-ethoxyphenoxy)methyl]-, Hydrochloride

21. Ici-58834

22. Viloxazine Hydrochloride (usan)

23. Ccris 1915

24. Viloxacina Clorhidrato [spanish]

25. Einecs 252-638-6

26. Unii-oqw30i1332

27. Prestwick_734

28. Vivalan (tn)

29. Cloridrato De Viloxazina

30. 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine Hydrochloride

31. Chlorhydrate De Viloxazine

32. 2-(2-ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine Hydrochloride

33. Dsstox_cid_31511

34. Dsstox_rid_97396

35. Dsstox_gsid_57722

36. Schembl300741

37. Chembl2106483

38. Dtxsid8057722

39. Glxc-25714

40. Tox21_113955

41. Viloxazine Hydrochloride [mi]

42. Akos015847050

43. At27980

44. Ccg-220828

45. Viloxazine Hydrochloride [mart.]

46. Ncgc00262964-01

47. Viloxazine Hydrochloride [who-dd]

48. Cas-35604-67-2

49. A6217

50. Ft-0675815

51. Ft-0675816

52. Ft-0675817

53. Ft-0675818

54. Ft-0675819

55. Viloxazine Hydrochloride [orange Book]

56. D02572

57. 2-(o-ethoxyphenoxymethyl)morpholine Hydrochloride

58. 604e672

59. Sr-01000872636

60. Sr-01000872636-1

61. W-110863

62. 2-(2-ethoxy-phenoxymethyl)-morpholine; Hydrochloride

63. 2-[(2-ethoxyphenoxy)-methyl]morpholine Hydrochloride

64. Q27285797

65. 2-(2-ethoxy-phenoxymethyl)-tetra-hydro-1,4-oxazine Hydrochloride

66. (+/-)-morpholine, 2-((2-ethoxyphenoxy)methyl)-, Hydrochloride

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 273.75 g/mol
Molecular Formula C13H20ClNO3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Exact Mass273.1131712 g/mol
Monoisotopic Mass273.1131712 g/mol
Topological Polar Surface Area39.7 Ų
Heavy Atom Count18
Formal Charge0
Complexity213
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antidepressive Agents, Second-Generation

A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)


Adrenergic Uptake Inhibitors

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)


4.2 FDA Pharmacological Classification
4.2.1 Pharmacological Classes
Cytochrome P450 2B6 Inhibitors [MoA]; Cytochrome P450 2D6 Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Norepinephrine Reuptake Inhibitor [EPC]; Norepinephrine Uptake Inhibitors [MoA]; Cytochrome P450 1A2 Inhibitors [MoA]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2025-01-24

Pay. Date : 2024-12-24

DMF Number : 39333

Submission : 2023-12-30

Status : Active

Type : II

Biophore

02

German Wound Congress
Not Confirmed

03

Apotex Pharmachem Inc

Canada

USDMF

arrow
German Wound Congress
Not Confirmed

03

German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-12-17

Pay. Date : 2024-10-21

DMF Number : 40648

Submission : 2024-11-07

Status : Active

Type : II

blank

04

Curia Spain Sau

U.S.A

USDMF

arrow
German Wound Congress
Not Confirmed

04

German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-05-21

Pay. Date : 2024-05-10

DMF Number : 39826

Submission : 2024-04-12

Status : Active

Type : II

blank

05

Lee Pharma Ltd

India

USDMF

arrow
German Wound Congress
Not Confirmed

05

German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39582

Submission : 2024-03-12

Status : Active

Type : II

blank

06

German Wound Congress
Not Confirmed

06

German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-12-13

Pay. Date : 2024-10-31

DMF Number : 40485

Submission : 2024-09-27

Status : Active

Type : II

blank

07

German Wound Congress
Not Confirmed

07

German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-12-17

Pay. Date : 2024-11-22

DMF Number : 38637

Submission : 2023-08-25

Status : Active

Type : II

blank

08

German Wound Congress
Not Confirmed

09

German Wound Congress
Not Confirmed

09

German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39715

Submission : 2024-06-04

Status : Active

Type : II

blank

10

German Wound Congress
Not Confirmed

10

German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2025-03-07

Pay. Date : 2025-01-30

DMF Number : 37860

Submission : 2022-12-27

Status : Active

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696617000,"product":"VILOXAZINE HYDROCHLORIDE","address":"SANALI INFO PARK, A BLOCK","city":"ROAD NO.2, BANJARA HILLS, HYDERABAD","supplier":"NEULAND LABORATORIES","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA METROP","customer":"TO THE ORDER OF","customerCountry":"UNITED STATES","quantity":"509.78","actualQuantity":"509.78","unit":"KGS","unitRateFc":"1200","totalValueFC":"603609.6","currency":"USD","unitRateINR":98548.393424614551,"date":"07-Oct-2023","totalValueINR":"50238000","totalValueInUsd":"603609.6","indian_port":"Hyderabad Air","hs_no":"29349920","bill_no":"4456337","productDescription":"API","marketType":"","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SANALI INFO PARK, A BLOCK, ROAD NO.2, BANJARA HILLS, HYDERABAD","customerAddress":""}]
07-Oct-2023
07-Oct-2023
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Qelbree (viloxazine HCl) is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.


Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Qelbree

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 27, 2025

blank

01

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : Qelbree (viloxazine HCl) is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

Product Name : Qelbree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 27, 2025

blank

Details:

An agreement aims to seek regulatory approval for Qelbree, an extended-release formulation of viloxazine for ADHD in children and adults.


Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Qelbree

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Moksha8 Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 05, 2024

blank

02

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : An agreement aims to seek regulatory approval for Qelbree, an extended-release formulation of viloxazine for ADHD in children and adults.

Product Name : Qelbree

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

July 05, 2024

blank

Details:

At daily flexible-dose 200 to 600mg, Phase III trial met primary endpoint showing reduction change from baseline of Adult ADHD Investigator Symptom Rating Scale total score at end of study was statistically significantly greater in adults treated with Qelbree versus placebo.


Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Qelbree

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 29, 2022

blank

03

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : At daily flexible-dose 200 to 600mg, Phase III trial met primary endpoint showing reduction change from baseline of Adult ADHD Investigator Symptom Rating Scale total score at end of study was statistically significantly greater in adults treated with Qe...

Product Name : Qelbree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 29, 2022

blank

Details:

If approved by the FDA, the Company is preparing for the commercial launch of SPN-812 for the treatment of ADHD in pediatric patients in the second quarter of 2021.


Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Qelbree

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 22, 2021

blank

04

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : If approved by the FDA, the Company is preparing for the commercial launch of SPN-812 for the treatment of ADHD in pediatric patients in the second quarter of 2021.

Product Name : Qelbree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 22, 2021

blank

Details:

The approval of Qelbree is supported by data from an extensive development program consisting of four Phase III clinical trials that studied more than 1000 pediatric patients from the age of 6 to 17 years.


Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Qelbree

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 04, 2021

blank

05

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : The approval of Qelbree is supported by data from an extensive development program consisting of four Phase III clinical trials that studied more than 1000 pediatric patients from the age of 6 to 17 years.

Product Name : Qelbree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 04, 2021

blank

Details:

At a daily dose of SPN-812 up to 600mg, the trial met the primary endpoint with robust statistical significance (p=0.0040) compared to placebo in improving the symptoms of ADHD from baseline to end of study as measured by ADHD Investigator Symptom Rating Scale (AISRS).


Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Qelbree

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 22, 2020

blank

06

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : At a daily dose of SPN-812 up to 600mg, the trial met the primary endpoint with robust statistical significance (p=0.0040) compared to placebo in improving the symptoms of ADHD from baseline to end of study as measured by ADHD Investigator Symptom Rating...

Product Name : Qelbree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 22, 2020

blank

Details:

SPN-812, if approved by the FDA, will be the first truly new therapy to treat ADHD in a decade


Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Qelbree

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 22, 2020

blank

07

German Wound Congress
Not Confirmed
German Wound Congress
Not Confirmed

Details : SPN-812, if approved by the FDA, will be the first truly new therapy to treat ADHD in a decade

Product Name : Qelbree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 22, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions
Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   

Impressions: 7234

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

#PharmaFlow by PHARMACOMPASS
24 Oct 2024

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 11324753

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2029-09-04

blank

02

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 12121523

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2029-09-04

blank

03

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 9662338

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 211964

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-04-02

blank

04

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 9603853

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2033-02-07

blank

05

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 12121523

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2029-09-04

blank

06

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 9603853

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2033-02-07

blank

07

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 12121523

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2029-09-04

blank

08

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 9603853

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2033-02-07

blank

09

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 11458143

Drug Substance Claim :

Drug Product Claim :

Application Number : 211964

Patent Use Code : U-727

Delist Requested :

Patent Use Description : FOR THE TREATMENT OF A...

Patent Expiration Date : 2029-09-04

blank

10

arrow
German Wound Congress
Not Confirmed
arrow
German Wound Congress
Not Confirmed

VILOXAZINE HYDROCHLORIDE

US Patent Number : 9358204

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 211964

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-02-07

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 35604-67-2 / Viloxazine Hydrochloride API manufacturers, exporters & distributors?

Viloxazine Hydrochloride manufacturers, exporters & distributors 1

69

PharmaCompass offers a list of Viloxazine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Viloxazine Hydrochloride manufacturer or Viloxazine Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Viloxazine Hydrochloride manufacturer or Viloxazine Hydrochloride supplier.

PharmaCompass also assists you with knowing the Viloxazine Hydrochloride API Price utilized in the formulation of products. Viloxazine Hydrochloride API Price is not always fixed or binding as the Viloxazine Hydrochloride Price is obtained through a variety of data sources. The Viloxazine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Viloxazine Hydrochloride

Synonyms

35604-67-2, 2-((2-ethoxyphenoxy)methyl)morpholine hydrochloride, Viloxazine hcl, Vivalan, Emovit, Vicilan

Cas Number

35604-67-2

Unique Ingredient Identifier (UNII)

OQW30I1332

About Viloxazine Hydrochloride

A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.

Viloxazine Hydrochloride Manufacturers

A Viloxazine Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Viloxazine Hydrochloride, including repackagers and relabelers. The FDA regulates Viloxazine Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Viloxazine Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Viloxazine Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Viloxazine Hydrochloride Suppliers

A Viloxazine Hydrochloride supplier is an individual or a company that provides Viloxazine Hydrochloride active pharmaceutical ingredient (API) or Viloxazine Hydrochloride finished formulations upon request. The Viloxazine Hydrochloride suppliers may include Viloxazine Hydrochloride API manufacturers, exporters, distributors and traders.

click here to find a list of Viloxazine Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Viloxazine Hydrochloride USDMF

A Viloxazine Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Viloxazine Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Viloxazine Hydrochloride DMFs exist exist since differing nations have different regulations, such as Viloxazine Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Viloxazine Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Viloxazine Hydrochloride USDMF includes data on Viloxazine Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Viloxazine Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Viloxazine Hydrochloride suppliers with USDMF on PharmaCompass.

Viloxazine Hydrochloride NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Viloxazine Hydrochloride as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Viloxazine Hydrochloride API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Viloxazine Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Viloxazine Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Viloxazine Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Viloxazine Hydrochloride suppliers with NDC on PharmaCompass.

Viloxazine Hydrochloride GMP

Viloxazine Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Viloxazine Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Viloxazine Hydrochloride GMP manufacturer or Viloxazine Hydrochloride GMP API supplier for your needs.

Viloxazine Hydrochloride CoA

A Viloxazine Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Viloxazine Hydrochloride's compliance with Viloxazine Hydrochloride specifications and serves as a tool for batch-level quality control.

Viloxazine Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Viloxazine Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Viloxazine Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Viloxazine Hydrochloride EP), Viloxazine Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Viloxazine Hydrochloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty